全文获取类型
收费全文 | 40704篇 |
免费 | 2869篇 |
国内免费 | 1118篇 |
专业分类
耳鼻咽喉 | 201篇 |
儿科学 | 927篇 |
妇产科学 | 535篇 |
基础医学 | 6457篇 |
口腔科学 | 819篇 |
临床医学 | 2698篇 |
内科学 | 6800篇 |
皮肤病学 | 758篇 |
神经病学 | 3318篇 |
特种医学 | 978篇 |
外国民族医学 | 5篇 |
外科学 | 4312篇 |
综合类 | 3724篇 |
现状与发展 | 3篇 |
一般理论 | 4篇 |
预防医学 | 2563篇 |
眼科学 | 481篇 |
药学 | 5603篇 |
3篇 | |
中国医学 | 1436篇 |
肿瘤学 | 3066篇 |
出版年
2023年 | 699篇 |
2022年 | 948篇 |
2021年 | 1612篇 |
2020年 | 1334篇 |
2019年 | 2238篇 |
2018年 | 2119篇 |
2017年 | 1489篇 |
2016年 | 1096篇 |
2015年 | 1316篇 |
2014年 | 2040篇 |
2013年 | 2231篇 |
2012年 | 1854篇 |
2011年 | 2157篇 |
2010年 | 1702篇 |
2009年 | 1618篇 |
2008年 | 1558篇 |
2007年 | 1455篇 |
2006年 | 1256篇 |
2005年 | 1257篇 |
2004年 | 1084篇 |
2003年 | 961篇 |
2002年 | 701篇 |
2001年 | 643篇 |
2000年 | 540篇 |
1999年 | 492篇 |
1998年 | 410篇 |
1997年 | 384篇 |
1996年 | 336篇 |
1995年 | 335篇 |
1994年 | 271篇 |
1993年 | 203篇 |
1992年 | 171篇 |
1991年 | 175篇 |
1990年 | 137篇 |
1989年 | 131篇 |
1987年 | 109篇 |
1986年 | 110篇 |
1985年 | 694篇 |
1984年 | 894篇 |
1983年 | 683篇 |
1982年 | 814篇 |
1981年 | 850篇 |
1980年 | 640篇 |
1979年 | 650篇 |
1978年 | 413篇 |
1977年 | 382篇 |
1976年 | 413篇 |
1975年 | 363篇 |
1974年 | 259篇 |
1973年 | 264篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
33.
34.
Hiroto Kinoshita Hitomi Nishioka Aya Ikeda Kyoko Ikoma Yoichi Sameshima Hidehisa Ohi Mizuki Tatsuno Junka Kouyama Chiaki Kawamoto Tomohiro Mitsui Yuko Tamura Yu Hashimoto Masashi Nishio Tsuyoshi Ogashiwa Yusuke Saigusa Shin Maeda Hideaki Kimura Reiko Kunisaki Kazuhiko Koike 《Journal of gastroenterology and hepatology》2019,34(11):1929-1939
35.
36.
《Journal of the American Medical Directors Association》2020,21(3):439.e9-439.e13
Background/ObjectivesPolypharmacy and multimorbidity is a threat to older people; hence, listing approaches should support physicians to optimize medication. The FORTA (Fit fOR The Aged) classification of drug appropriateness for older people provides positive or negative labels: A (A-bsolutely), B (B-eneficial), C (C-areful), and D (D-on't). Based on these categories, FORTA-labeled drug lists were developed in 7 European countries or regions; the same approach was used to develop a U.S.-FORTA List reflecting the country-specific availability and usage of drugs.Design/SettingA 2-step Delphi-type approach was employed to add, remove, or relabel drugs from the listing proposal and to add or remove new indications. The proposal utilized the European (EURO)-FORTA list as template.ParticipantsEight US-based geriatricians/pharmacists served as raters. Measurements: Raters gave recommendations and comments on the list items.ResultsThe first U.S.-FORTA List contains 273 items aligned to 27 main indication groups; 30 drugs and drug groups were added, and 23 removed as being unavailable in the United States. The highest percentage of changes in FORTA labels as compared to the EURO-FORTA List occurred for sleep disorders associated with dementia (40%). In 8 indications, the labels for 11 items were different from the proposal. Thus, for the majority of the items (n = 232, 95.5%), the proposals were accepted by the US raters. Only 16 (6.6%) of the proposed items (n = 243) had to be re-evaluated in the second round as a result of inconsistent rating in the first round.Conclusions and ImplicationsThe U.S.-FORTA List addresses the appropriateness of drugs for older people in the United States reflecting country-specific availability, usage, and expert rating. As shown for the FORTA list in Europe, this listing approach is among the few that are clinically validated and improve well-being and geriatric outcomes. The U.S.-FORTA List now largely enhances the global availability of this approach. 相似文献
37.
Michelle Linda Ferderbar Thomas E. Doyle Reza Samavi David Koff 《Journal l'Association canadienne des radiologistes》2019,70(2):119-124
Several regulatory bodies have agreed that low-dose radiation used in medical imaging is a weak carcinogen that follows a linear, non-threshold model of cancer risk. While avoiding radiation is the best course of action to mitigate risk, computed tomography (CT) scans are often critical for diagnosis. In addition to the as low as reasonably achievable principle, a more concrete method of dose reduction for common CT imaging exams is the use of a diagnostic reference level (DRL). This paper examines Canada's national DRL values from the recent CT survey and compares it to published provincial DRLs as well as the DRLs in the United Kingdom and the United States of America for the 3 most common CT exams: head, chest, and abdomen/pelvis. Canada compares well on the international scale, but it should consider using more electronic dose monitoring solutions to create a culture of dose optimization. 相似文献
38.
目的研究丹蛭降糖胶囊对糖尿病肾病大鼠的肾脏病理改变和足细胞自噬水平的影响,初步探讨其相应的作用机制。方法选取GK大鼠40只,采用醋酸脱氧皮质酮-盐皮下注射联合高脂饲料喂养诱导糖尿病肾病模型。造模成功后随机分为模型组、丹蛭降糖胶囊低剂量组[0.54 g/(kg·d)]、高剂量组[1.08 g/(kg·d)]、缬沙坦组[10 mg/(kg·d)],每组10只。另选取10只同周龄正常Wistar大鼠作为正常组。模型组和正常组给予等容积生理盐水。连续灌胃10周后检测空腹血糖(FBG)、血肌酐(SCr)、尿素氮(BUN)和尿微量蛋白(U-mAlb)。Western Blot检测肾小球p-mTOR、p-S6K1、Beclin-1、LC3和Nephrin蛋白的表达,HE染色和PAS染色后于光镜下观察肾脏病理变化,电镜下观察各组亚细胞形态结构变化。结果与正常组比较,模型组FBG、SCr、BUN、U-mAlb水平升高(P<0.01);与模型组比较,丹蛭降糖胶囊低、高剂量组和缬沙坦组U-mAlb水平降低(P<0.01)。模型组可见肾小球基底膜增厚,系膜基质沉积,足细胞损伤,各用药组均有不同程度改善,丹蛭降糖胶囊高剂量组足细胞内有较多自噬体形成。与正常组比较,模型组p-mTOR、p-S6K1的表达增高,Nephrin、Beclin-1和LC3的表达水平降低(P<0.01);与模型组比较,各用药组p-mTOR、p-S6K1的表达下降,Nephrin、Beclin-1和LC3的表达增高(P<0.01)。丹蛭降糖胶囊高剂量组和缬沙坦组Beclin1、LC3Ⅱ/LC3Ⅰ水平较丹蛭降糖胶囊低剂量组升高(P<0.05)。结论丹蛭降糖胶囊具有减轻糖尿病肾病大鼠U-mAIb、足细胞损伤及相关肾脏病理改变的作用,其机制可能与抑制mTOR/S6K1信号通路进而提高足细胞的自噬活性有关。 相似文献
39.
目的探讨负载 IL-4 和 BMP-2 的氧化石墨烯(graphene oxide,GO)-羧甲基壳聚糖(carboxymethyl chitosan,CMC)凝胶诱导巨噬细胞 M2 型分化及对 BMSCs 成骨分化的影响。方法取 CMC、GO 制备混合溶液后,分别添加 PBS、IL-4、BMP-2 或 IL-4+BMP-2,在交联剂作用下制备单纯或负载不同因子的 GO-CMC 凝胶支架;取单纯 GO-CMC 凝胶表征观测,包括大体、扫描电镜及傅里叶变换红外吸收光谱仪(Fourier transform infrared spectroscopy,FTIR)检测,以单纯 CMC 凝胶作为对照;取负载不同因子的 GO-CMC 凝胶行体外缓释实验。取 4~5 周龄 SPF 级 SD 雌性大鼠分离培养巨噬细胞,分别与单纯以及负载不同因子的 GO-CMC 凝胶培养,24 h 后行 CD206 免疫荧光检测巨噬细胞分化情况;取第 3 代大鼠 BMSCs 分别与单纯以及负载不同因子的 GO-CMC 凝胶成骨诱导培养,10 d 后行 ALP 染色观测早期成骨,21 d 行茜素红染色观测晚期成骨。结果大体观察 GO-CMC 凝胶呈棕色、半透明状;扫描电镜观察示,GO-CMC 凝胶孔径及孔壁厚度与单纯 CMC 凝胶相似,但内壁粗糙度增加;FTIR 检测显示 CMC 发生聚合形成凝胶。体外缓释实验示 3 种负载不同因子的 GO-CMC 凝胶缓释性能相似,均呈线性缓慢释放因子。CD206 免疫荧光检测示 GO-CMC 凝胶可诱导巨噬细胞 M2 型分化,ALP 及茜素红染色示 GO-CMC 凝胶可诱导 BMSCs 成骨分化;其中负载 IL-4+BMP-2 的 GO-CMC 凝胶作用最显著(P<0.05)。 结论负载 IL-4 和 BMP-2 的 GO-CMC 凝胶可诱导巨噬细胞 M2 型分化,增强 BMSCs 成骨分化能力,为后期骨缺损修复及骨免疫调节研究提供了新的策略。 相似文献
40.
Hsin-Yi Tseng Jan Dreyer Abdullah Al Emran Dilini Gunatilake Mehdi Pirozyan Carleen Cullinane Ken Dutton-Regester Helen Rizos Nicholas K. Hayward Grant McArthur Peter Hersey Jessamy Tiffen Stuart Gallagher 《International journal of cancer. Journal international du cancer》2020,147(8):2176-2189
The treatment of melanoma has been markedly improved by the introduction of targeted therapies and checkpoint blockade immunotherapy. Unfortunately, resistance to these therapies remains a limitation. Novel anticancer therapeutics targeting the MCL1 anti-apoptotic protein have shown impressive responses in haematological cancers but are yet to be evaluated in melanoma. To assess the sensitivity of melanoma to new MCL1 inhibitors, we measured the response of 51 melanoma cell lines to the novel MCL1 inhibitor, S63845. Additionally, we assessed combination of this drug with inhibitors of the bromodomain and extra-terminal (BET) protein family of epigenetic readers, which we postulated would assist MCL1 inhibition by downregulating anti-apoptotic targets regulated by NF-kB such as BCLXL, BCL2A1 and XIAP, and by upregulating pro-apoptotic proteins including BIM and NOXA. Only 14% of melanoma cell lines showed sensitivity to S63845, however, combination of S63845 and I-BET151 induced highly synergistic apoptotic cell death in all melanoma lines tested and in an in vivo xenograft model. Cell death was dependent on caspases and BAX/BAK. Although the combination of drugs increased the BH3-only protein, BIM, and downregulated anti-apoptotic proteins such as BCL2A1, the importance of these proteins in inducing cell death varied between cell lines. ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL, respectively, induced further cell death when combined with S63845 and I-BET151. The combination of MCL1 and BET inhibition appears to be a promising therapeutic approach for metastatic melanoma, and presents opportunities to add further BCL2 family inhibitors to overcome treatment resistance. 相似文献